Chemomab shareholders approve CEO Dale Pfost employment terms at special meeting

Chemomab Therapeutics Ltd.

Special meeting held Oct 25, 2021; 42.74% of outstanding shares represented.
Proposal to approve CEO Dr. Dale Pfost's employment terms passed with 96.3M for, 1.2M against.
Pfost was engaged as CEO on September 1, 2021.
Vote satisfied requisite majority under Israeli Companies Law.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.